Indivior accelerates RB copacker supply deal termination to Jan 15, 2027

Indivior Pharmaceuticals, Inc.

Indivior UK and Reckitt Benckiser Healthcare UK terminated Copacker Supply Agreement effective Jan 15, 2027, vs original Dec 31, 2027.
RB to manufacture additional volumes of SUBOXONE/SUBUTEX tablets before termination; Indivior identified a new supplier.
Indivior to pay RB costs (under absorption, asset disposal, redundancy, incentive) that are fixed/capped and stated as not material.
New supplier agreement not expected to be material and enforceable only after validation of manufacturing process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.